{"disease":{"id":"cancer-advanced","name":"cancer advanced"},"drugs":{"marketed":[{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of breast cancer in postmenopausal women with hormone receptor-positive or hormone receptor-negative advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"aromatase-inhibitor","indication_name":"Treatment of hormone receptor-positive or hormone receptor-negative breast cancer in postmenopausal women with advanced disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aromatase inhibitor","generic_name":"aromatase-inhibitor","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aromatase","drug_class":"Aromatase inhibitor","quality_score":25,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":31,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05217381","title":"Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status","phase":"","overall_status":"COMPLETED","enrollment_count":18533,"lead_sponsor_name":"MedSIR","has_results":false},{"nct_id":"NCT04739722","title":"Colorectal Cancer and Pre-Cancerous Adenoma Non-Invasive Detection Test Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":14263,"lead_sponsor_name":"Geneoscopy, Inc.","has_results":true},{"nct_id":"NCT04786704","title":"A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population","phase":"","overall_status":"COMPLETED","enrollment_count":12106,"lead_sponsor_name":"Changhai Hospital","has_results":false},{"nct_id":"NCT06059963","title":"A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Universal Diagnostics","has_results":false},{"nct_id":"NCT04287335","title":"Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in China","phase":"","overall_status":"COMPLETED","enrollment_count":4758,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06220617","title":"Multi-omics Study for Early Detection of Colorectal Cancer (MOED-CRC)","phase":"","overall_status":"RECRUITING","enrollment_count":3600,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT06738511","title":"Validation of a Molecular Signature for Early Detection of Colorectal Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":3421,"lead_sponsor_name":"ADVANCED MARKER DISCOVERY S.L.","has_results":false},{"nct_id":"NCT07386847","title":"A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Pfizer","has_results":false},{"nct_id":"NCT05564377","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":2900,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05255588","title":"A Stool DNA-based SDC2 Methylation Test for the Early Detection of Colorectal Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2358,"lead_sponsor_name":"Genomictree, Inc.","has_results":false},{"nct_id":"NCT05957068","title":"Breast Cancer Exercise Intervention Study","phase":"NA","overall_status":"RECRUITING","enrollment_count":2156,"lead_sponsor_name":"National Cancer Centre, Singapore","has_results":false},{"nct_id":"NCT07401199","title":"Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Qun Zhao","has_results":false},{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT07426094","title":"PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Affidea Nu-med Center of Oncological DIagnostics and Therapy","has_results":false},{"nct_id":"NCT05166694","title":"Evaluating Personalized Therapeutics Clinic (PTC) on Drug-Drug Interactions and Drug-Gene Interactions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"University of Chicago","has_results":false},{"nct_id":"NCT03828396","title":"Diagnosis of Colorectal Cancer and Advanced Adenoma Using Cancer-specific Methylation Signatures","phase":"","overall_status":"UNKNOWN","enrollment_count":1300,"lead_sponsor_name":"Shanghai Zhongshan Hospital","has_results":false},{"nct_id":"NCT04792684","title":"Collection of Samples USOPTIVAL Study","phase":"","overall_status":"RECRUITING","enrollment_count":1300,"lead_sponsor_name":"Universal Diagnostics","has_results":false},{"nct_id":"NCT04722055","title":"A Multicenter Clinical Trial of Stool-based DNA Testing for Early Detection of Colon Cancer in China","phase":"","overall_status":"COMPLETED","enrollment_count":1273,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT04141397","title":"Real-world Clinical Effectiveness of Whole Genome and Transcriptome Analysis to Guide Advanced Cancer Care","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"British Columbia Cancer Agency","has_results":false},{"nct_id":"NCT07343349","title":"Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions","phase":"NA","overall_status":"RECRUITING","enrollment_count":1016,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT06258434","title":"Liquid Biopsy Based Multiomics Study for Colorectal Cancer Early Screening","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"Sir Run Run Shaw Hospital","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT05216432","title":"First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":930,"lead_sponsor_name":"Relay Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05406999","title":"Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":900,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT00911170","title":"PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":847,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT05374369","title":"Retrospective Analysis of Colorectal Cancer Screening Results","phase":"","overall_status":"COMPLETED","enrollment_count":822,"lead_sponsor_name":"Creative Biosciences (Guangzhou) Co., Ltd.","has_results":false},{"nct_id":"NCT06093425","title":"Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":820,"lead_sponsor_name":"Suzhou Transcenta Therapeutics Co., Ltd.","has_results":false},{"nct_id":"NCT07485166","title":"Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic Health Records Databases","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":810,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06210776","title":"A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Daiichi Sankyo","has_results":false},{"nct_id":"NCT01231347","title":"QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"NantCell, Inc.","has_results":true},{"nct_id":"NCT05379985","title":"Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":754,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT05380414","title":"Profiling Program of Advanced/Metastatic Pancreatic Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":750,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT05592886","title":"A Novel Oral Synbiotic Formula in Reducing Advanced Adenoma Recurrence and Colorectal Neoplasia-related Bacterial Gene Markers","phase":"NA","overall_status":"RECRUITING","enrollment_count":649,"lead_sponsor_name":"Chinese University of Hong Kong","has_results":false},{"nct_id":"NCT05594095","title":"SNF Platform Study of HR+/ HER2-advanced Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":620,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT02115282","title":"Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":608,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06040541","title":"Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":604,"lead_sponsor_name":"Revolution Medicines, Inc.","has_results":false},{"nct_id":"NCT01802632","title":"AZD9291 First Time In Patients Ascending Dose Study","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":603,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT07004582","title":"Lab Research Using Mini-tumors to Study Prostate Cancer Treatments","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Maastricht Radiation Oncology","has_results":false},{"nct_id":"NCT06936878","title":"BOLSTER: Learning New Skills to Thrive","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06866782","title":"European Registry of Next Generation Imaging in Advanced Prostate Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Fundacio Puigvert","has_results":false},{"nct_id":"NCT04406662","title":"Routine Evaluation of People Living With Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT05875584","title":"Exploratory Study of a Novel Based rbcDNA Liquid Biopsy Technique for Colorectal Cancer Early Detection","phase":"","overall_status":"COMPLETED","enrollment_count":598,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT00585195","title":"A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":596,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05919264","title":"FOG-001 in Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":595,"lead_sponsor_name":"Parabilis Medicines, Inc.","has_results":false},{"nct_id":"NCT04912687","title":"Implementing Circulating Tumor DNA Analysis at Initial Diagnosis to Improve Management of Advanced NSCLC Patients","phase":"NA","overall_status":"COMPLETED","enrollment_count":581,"lead_sponsor_name":"Institut Bergonié","has_results":false},{"nct_id":"NCT03504397","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06982521","title":"Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Relay Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03875781","title":"Non Inferiority Study of Preoperative Chemotherapy Without Pelvic Irradiation for Rectal Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":540,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}